-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33

Benzinga·11/11/2025 14:53:39
Listen to the news
Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $38 to $33.